araag2/HINT huggingface dataset:
Clinical trial NCT00611858 (phase 2, status: terminated)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, 5-fluorouracil
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, FC1=CNC(=O)NC1=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the rectum that begins within 15cm of the
             anal verge as determined by sigmoidoscopy and/or colonoscopy, with no evidence of
             distant metastatic disease. A complete colonoscopy to the cecum is recommended prior
             to initiating protocol therapy.

          -  Staging with transrectal ultrasound or endorectal coil Magnetic resonance imaging
             (MRI) to confirm clinical stage of T3 or T4 or lymph node positive rectal
             adenocarcinoma

          -  Tumor is K-ras wildtype by method of choice at respective institution (testing codons
             12 and 13)

          -  Performance status: Eastern Cooperative Oncology Group Performance Score (ECOG PS)
             less than or equal to 2

          -  18 years of age or older

          -  No evidence of metastatic disease by abdominal/pelvic (Computed tomography) CT and
             chest imaging

          -  Adequate bone marrow, renal,and hepatic function as outlined in protocol

          -  All patients will be evaluated by a surgeon and considered a candidate for definitive
             surgery

          -  Coumadin or heparin management for line care of other indications is permitted. The
             International Normalised Ratio (INR) will be monitored weekly in patients taking
             coumadin.

        Exclusion Criteria:

          -  Prior treatment for this malignancy

          -  Prior history of pelvic radiation therapy

          -  Prior history of 5-FU based or EGFR receptor inhibitor therapy

          -  Prior history of an allergic reaction to a monoclonal antibody

          -  Uncontrolled serious medical or psychiatric illness

          -  Significant history of uncontrolled cardiac disease

          -  Sexually active women of childbearing potential must use an effective method of birth
             control during the course of the study

          -  Unwilling to agree to pre and post-cetuximab sigmoidoscopy and biopsy
Clinical trial NCT00040456 (phase 2, status: terminated)
Conditions: hemoglobin sc disease
ICD codes: D56.5, D56.4, D58.2, D59.5, D59.6, R82.3
Drugs: mg pidolate, placebo
SMILES: OC(=O)[C@@H]1CCC(=O)N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion criteria:

        This protocol is open to male and female patients of all races with a diagnosis of severe
        sickle hemoglobinopathy providing they also satisfy the following eligibility criteria:

          -  Adult and pediatric patients with Hb SC disease who are able to swallow the Mg
             pidolate preparation and who have had at least one prior painful crisis.

        Exclusion Criteria:

          -  Patients transfused within 90 days of study entry,

          -  Patients with elevated (>1.5 times upper limit of normal for age) BUN, creatinine, or
             liver function tests > 3 times the upper limit of normal for age,

          -  Patients who take a magnesium-containing medication (Mylanta, Maalox, etc.) on a
             regular (i.e., more than 2 days per week) basis.

          -  Patients with progressive neuromuscular disease or patients who are treated with a
             calcium channel blocker.

          -  Pregnancy
Clinical trial NCT00267748 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sunitinib malate continuous daily dosing, sunitinib malate schedule 4/2
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced renal cell carcinoma of clear cell origin or a component of clear cell
             histology.

          -  Measurable disease

        Exclusion Criteria:

          -  Prior systemic therapy of any kind for advanced renal cell cancer

          -  History of brain metastases

          -  Uncontrolled hypertension
Clinical trial NCT00448214 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: ym150, warfarin
SMILES: COC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

        Subjects are eligible for the study if all of the following apply:

          -  Subject has paroxysmal permanent or persistent NVAF

          -  Subject has INR of 2.0 or below and an aPTT ≤ 1.5 times the upper limit of normal at
             the baseline visit.

          -  Legal minimum age requirement (country-specific).

          -  Written informed consent has been obtained.

        Exclusion Criteria:

          -  History of heart valve disorders

          -  History of rheumatic fever.

          -  History of stroke and/or systemic embolism (including TIA).

          -  History of Acute Coronary Syndrome (ACS).

          -  Indication for warfarin other than NVAF.

          -  Known hemorrhagic disorder and/or coagulation disorder.

          -  Active bleeding or any condition associated with increased risk of bleeding.
Clinical trial NCT01199289 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: amg 827, placebo, amg 827, amg 827
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women 18 to 65 years of age

          -  Percent of predicted FEV1 ≥ 50% and ≤ 80%

          -  At least 12% reversibility over pre-bronchodilator FEV1

          -  Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent.

          -  Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points

        Exclusion Criteria:

          -  Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit

          -  History of chronic obstructive pulmonary disease or other chronic pulmonary condition
             other than asthma

          -  Any uncontrolled or clinically significant systemic disease (eg, uncontrolled
             diabetes, liver disease)
Clinical trial NCT01539902 (phase 2, status: unknown status)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or non-pregnant females age 16 to 65 years inclusive.

          2. Written informed consent obtained from patient or parents/guardian.

          3. Patients with SLE fulfilling American Rheumatism Association criteria and SLEDAI
             score>8 or BILAG score A/B.

          4. Patients with newly diagnosed World Health Organization (WHO) Class III or IV Lupus
             Nephritis

        Exclusion Criteria:

        Patients with any of the following are not eligible for enrollment into the study:

          1. Pregnant or nursing woman or women of childbearing potential except if
             post-menopausal, surgically sterile or using accepted method(s) of birth control or
             having negative pregnancy test.

          2. Participation in any research in which the patient received an investigational product
             within 30 days preceding the screening phase of this study.

          3. Those persons directly involved in the conduct of the study.

          4. Serum creatinine more than 250 µmol/L.

          5. White blood cell (WBC) count of less than 3.5 X 109/L.

          6. Active peptic ulcer disease.

          7. Active systemic infection.

          8. History of alcohol or substance abuse.

          9. History of malignancy within previous 5 years.

         10. Any serious medical conditions or disability, which in the opinion of the
             investigator, would interfere with treatment or assessment or preclude completion of
             this study.
Clinical trial NCT00464685 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: dexamethasone, sham injection
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older with diabetic macular edema

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids - Use of Warfarin/Heparin
Clinical trial NCT01222702 (phase 2, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: cadazolid, vancomycin, placebo-matching cadazolid, placebo-matching vancomycin
SMILES: OC[C@H]1CN(C(=O)O1)C1=CC(F)=C(OCC2(O)CCN(CC2)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O)C=C1, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, OC[C@H]1CN(C(=O)O1)C1=CC(F)=C(OCC2(O)CCN(CC2)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O)C=C1, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female

          -  At least 18 years of age

          -  With a diagnosis of Clostridium Difficile-associated diarrhea (CDAD): first occurrence
             or first recurrence.

        Key Exclusion Criteria:

          -  Concurrent life threatening condition.

          -  Immuno-compromised subjects, concomittant immuno-suppresive treatment.

          -  Concomitant antimicrobial treatment for CDAD.

          -  Any circumstances or conditions, which, in the opinion of the investigator, would
             affect full participation of the subject in the study or compliance with the protocol
Clinical trial NCT00003276 (phase 2, status: completed)
Conditions: gallbladder cancer
ICD codes: C23, D37.6
Drugs: irinotecan hydrochloride
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically proven gallbladder or bile duct
        carcinoma with metastatic or recurrent disease deemed unresectable and not considered a
        candidate for potentially curative therapy Measurable or evaluable disease No known active
        CNS disease Closed to bile duct carcinoma as of July 1999

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count at
        least 100,000/mm3 Hepatic: SGOT no greater than 5 times upper limit of normal (ULN)
        Bilirubin no greater than 1.5 mg/dL OR Bilirubin no greater than 2 times ULN in patients
        with biliary stents or percutaneous biliary catheters Renal: Creatinine no greater than 1.5
        mg/dL Cardiovascular: No New York Heart Association class III or IV heart disease Other:
        Nutritional intake at least 1200 kcal/day No uncontrolled infection or chronic debilitating
        disease Not pregnant or nursing Fertile patients must use effective contraception No
        uncontrolled seizure disorder No prior malignancy within 5 years except adequately treated
        basal cell/squamous cell carcinomas and adequately treated noninvasive carcinomas

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biological therapy or immunotherapy
        for recurrent or metastatic disease No concurrent biologic therapy Chemotherapy: No prior
        chemotherapy for recurrent or metastatic disease Prior adjuvant chemotherapy allowed if
        used as a radiation sensitizer for completely resected disease No other concurrent
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for
        recurrent or metastatic disease Prior adjuvant radiotherapy allowed if used as a radiation
        sensitizer for completely resected disease No radiotherapy to greater than 25% of bone
        marrow No radiotherapy within the past 4 weeks No concurrent radiotherapy Concurrent CNS
        radiation allowed Surgery: No post abdominal exploration (with or without resection) within
        the past 4 weeks Other: No concurrent medication for other medical conditions except for:
        Analgesics Chronic treatments for preexisting conditions Agents required for
        life-threatening medical conditions No laxatives
Clinical trial NCT01176903 (phase 1/phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: glycopyrrolate, tiotropium, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females patients aged 40-75 years;

          -  Written informed consent obtained;

          -  Diagnosis of moderate-severe COPD, according to the GOLD guidelines;

          -  Current or ex-smokers with a smoking history of ≥ 10 pack-years

          -  Post bronchodilator FEV1 between 40% and 80% predicted values (40% ≤ FEV1 < 80%),
             documented at screening visit ;

          -  Post bronchodilator FEV1/Forced Vital Capacity (FEV1/FVC) ≤ 0.70 (absolute value)
             documented at screening visit;

          -  Airway reversibility of at least 100 mL within 30 to 45 minutes after inhalation of
             ipratropium 80µg.

        Exclusion Criteria:

          -  History of chronic or seasonal allergy

          -  Blood eosinophil count above 600 per µl

          -  Clinically relevant findings on physical examination laboratory and ECG parameters at
             screening

          -  Occurrence of clinically relevant abnormalities in the 24-h Holter ECG recording at
             screening;

          -  Significant disease not related to COPD (eg. Myocardial infarction, stroke within the
             preceding 6 months);

          -  Respiratory tract infection (including upper tract) 4 weeks prior to study entry
             requiring changing treatment;

          -  Patients requiring oxygen therapy on a daily basis for chronic hypoxemia;

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any
             other significant lung disease which is considered to be clinically significant by the
             investigator.

          -  Intolerance/hypersensitivity or any contra-indication to treatment with M3 Antagonist
             or any of the excipients contained in the formulations used in the study.

          -  History of alcohol or substance abuse that in the opinion of the Investigator may be
             of clinical significance.

          -  Patients treated with slow-release oral or parental corticosteroids 8 weeks prior to
             Screening Visit.

          -  Patients treated with tiotropium in the 10 days prior to the Screening Visit;

          -  Pregnant or lactating women and female or male subjects not willing to use an
             acceptable method of contraception.
Clinical trial NCT01508156 (phase 1/phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: idx719, placebo
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC2=CC=C(C=C2N1)C1=CSC2=C1SC=C2C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All Participants

          -  Is in good general health.

          -  Agrees to use double-barrier method of birth control for at least 90 days after the
             last dose of study drugs.

          -  HCV Participants

          -  Has documented GT1, GT2, or GT3 chronic HCV infection.

        Exclusion Criteria:

          -  All Participants

          -  Is pregnant or breastfeeding.

        HCV Participants

          -  Has received prior HCV treatment.

          -  Is co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).
Clinical trial NCT01089543 (phase 2, status: completed)
Conditions: functional dyspepsia
ICD codes: K30
Drugs: rabeprazole, rabeprazole, rabeprazole, placebo
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        -Participants diagnosed as Functional Dyspepsia according to Rome III criteria.

        Exclusion criteria:

          -  Participants with neuropsychiatric disorder.

          -  Participants diagnosed with irritable bowel syndrome, inflammatory bowel disease and
             serious constipation.
Clinical trial NCT01221753 (phase 2, status: terminated)
Conditions: squamous cell carcinoma of the head and neck, human papilloma virus
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, A66.1, B97.7, R85.81, R85.82, R87.810, R87.811, R87.820
Drugs: docetaxel, cisplatin, 5-fu, cetuximab, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria

          -  Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or
             unknown primary that is HPV 16 positive as determined by ISH and p16 positive as
             determined by IHC.

          -  Stage 3 or 4 disease without evidence of distant metastases

          -  At least one evaluable or uni- or bi-dimensionally measurable lesion by RECIST 1.1
             criteria

          -  18 years of age or older

          -  No previous surgery, radiation therapy or chemotherapy for SSCHN is allowed at time of
             study entry

          -  ECOG Performance Status of 0 or 1

          -  No active alcohol addiction

          -  Adequate bone marrow, hepatic and renal function as defined in the protocol

          -  Women of child-bearing potential must have a negative pregnancy test within 7 days of
             starting treatment

        Exclusion Criteria

          -  Pregnant or breast feeding women or women and men of childbearing potential not
             willing to use adequate contraception while on treatment and for at least 3 months
             after

          -  Previous or current malignancies at other sites

          -  Symptomatic peripheral neuropathy of grade 2 or greater

          -  Symptomatic altered hearing greater than grade 2

          -  Other serious illnesses or medical conditions

          -  Patients that have experienced an involuntary weight loss of more than 25% of their
             body weight in the 2 months preceding study entry

          -  Concurrent treatment with any other anticancer therapy

          -  Participation in an investigational trial within 30 days of study entry
Clinical trial NCT01498185 (phase 2, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: dapagliflozin, placebo matching dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes with central lab Glycosylated hemoglobin (A1C) ≥ 7.0% and ≤ 10.0%

          -  Insulin use for at least 12 months and initiation immediately after diagnosis of
             diabetes

          -  Method of Insulin administration [multiple daily injections (MDI) or continuous
             subcutaneous Insulin infusion (CSII)] stable ≥ 3 months

          -  Stable basal Insulin dose ≥ 2 weeks

          -  Ages 18 to 65 years

          -  Central laboratory C-peptide value of < 0.7 ng/mL

          -  Body mass index (BMI) 18.5 to 35.0 kg/m2

        Exclusion Criteria:

          -  History of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY),
             pancreatic surgery or chronic pancreatitis

          -  Oral hypoglycemic agents

          -  History of diabetes ketoacidosis (DKA) within 24 weeks

          -  History of hospital admission for glycemic control within 6 months

          -  Frequent episodes of hypoglycemia (2 unexplained within 3 months) or hypoglycemic
             unawareness

          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or Serum total
             bilirubin > 2X Upper limit of normal (ULN)

          -  Abnormal Free T4 [if screening Thyroid Stimulating Hormone (TSH) abnormal]

          -  Estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease
             (MDRD) formula ≤ 60 mL/min/1.73m2

          -  Cardiovascular (CV)/Vascular Diseases within 6 months